FDA Approves Decnupaz, the First CD123-Targeting ADC for a Blood Cancer With Historically Dismal Prognosis

Overview

The U.S. Food and Drug Administration on May 27, 2026 approved pivekimab sunirine-pvzy (Decnupaz), a CD123-directed antibody-drug conjugate developed by AbbVie, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive blood cancer for which treatment options have been sharply limited, according to AbbVie’s press release on PR Newswire. The approval covers both newly diagnosed patients and those with relapsed or refractory disease, making Decnupaz the first antibody-drug conjugate and the first therapy that can be initiated in an outpatient setting for this indication.

What Is BPDCN

BPDCN is a malignancy of the dendritic cell lineage that typically manifests in patients in their 60s and 70s and is roughly three to four times more common in men than women, as the Elzonris HCP resource describes. Approximately 90% of patients present with skin lesions as the first sign of disease, though the cancer can rapidly spread to bone marrow, lymph nodes, and the central nervous system, per StatPearls on NCBI. Historically, median overall survival for BPDCN has been approximately 8 to 14 months after diagnosis, according to the Elzonris site, with intensive chemotherapy and stem cell transplantation offering the only paths to durable remission — and relapse rates remaining high even after those approaches.

The only previously approved drug for BPDCN was tagraxofusp-erzs (Elzonris), which the FDA cleared in 2018 and which works by inhibiting protein synthesis in CD123-expressing cells, as StatPearls notes. Decnupaz targets the same CD123 receptor but uses a different mechanism: it delivers an indolinobenzodiazepine pseudodimer payload that alkylates DNA, causing single-strand breaks without crosslinking and triggering apoptosis, according to AllSci’s report on the approval.

CADENZA Trial Results

The approval is supported by data from the Phase 1/2 CADENZA trial (NCT03386513), a multicenter, open-label, single-arm study, as described by the Oncology Nursing Society. In the 33 newly diagnosed patients enrolled without active central nervous system disease, 69.7% achieved a complete remission or clinical complete remission (CR/CRc), with a median duration of response of 9.7 months and a median follow-up of 21.5 months. Among those frontline patients, 39.4% subsequently received a stem cell transplant, indicating that Decnupaz can serve as a bridge to potentially curative consolidation, per AbbVie’s announcement.

In the 51 patients with relapsed or refractory BPDCN, the CR/CRc rate was 15.7%, with a median duration of response of 9.2 months and a median follow-up of 24.1 months, according to the Oncology Nursing Society. An additional 11.8% of those patients went on to receive stem cell transplantation.

Outpatient Administration and Safety

Decnupaz is dosed at 0.045 mg/kg intravenously over 15 to 30 minutes once every three weeks, as the Oncology Nursing Society reports. Its outpatient initiation is clinically significant in a disease where prior intensive chemotherapy regimens have typically required prolonged inpatient stays.

The drug carries a boxed warning for hepatotoxicity, including potentially fatal hepatic veno-occlusive disease. Additional warnings cover infusion-related reactions, edema, sulfite allergic reactions, and embryo-fetal toxicity, per AbbVie’s press release. The most common adverse reactions occurring in at least 20% of patients were edema, fatigue, musculoskeletal pain, hemorrhage, infusion-related reactions, nausea, and diarrhea.

Regulatory History and Development Background

The FDA granted Decnupaz Breakthrough Therapy Designation in October 2020 for relapsed or refractory BPDCN, along with Orphan Drug Designation and Priority Review, as AbbVie noted in its announcement. AbbVie submitted the biologics license application in September 2025.

The drug was originally discovered and developed by ImmunoGen, which AbbVie acquired in November 2023 for $10.1 billion, according to AllSci. Decnupaz is the first molecule from that acquisition to reach FDA approval.

What Investigators Said

Roopal Thakkar, Executive Vice President, R&D, Chief Scientific Officer at AbbVie, said: “For patients living with rare cancers, progress in research can be life‑changing. This approval delivers a new option for treating BPDCN and demonstrates our determination to drive meaningful advancements for patients affected by difficult-to-treat cancers.”

Naveen Pemmaraju, M.D., Professor of Leukemia at The University of Texas MD Anderson Cancer Center, said: “BPDCN is an aggressive disease with historically limited therapeutic options, particularly for patients whose disease has relapsed or become refractory. Pivekimab sunirine-pvzy is the first and only CD123 targeting ADC that can be initiated in an outpatient setting, offering a meaningful benefit for BPDCN patients in need of new treatment alternatives.”

Both quotes appear in AbbVie’s May 27 press release.

What We Don’t Know

The CADENZA data submitted to the FDA were generated from a Phase 1/2 trial, and overall survival results have not been reported from the full cohort. The low response rate in the relapsed or refractory setting — 15.7% composite CR/CRc — leaves open the question of how the drug will be positioned against other approaches after first-line failure. AbbVie has not disclosed pricing, nor has it stated when Decnupaz will be commercially available. The approval label does not address comparative effectiveness against tagraxofusp in the frontline setting, and a head-to-head trial between the two CD123-targeting agents has not been announced.